title: [Prophylactic prescription of low-molecular-weight heparin in the non-surgical setting: impact of recommendations].
abstract: OBJECTIVE
  Low-molecular-weight heparins (LMWH) had official approval for use for venous thromboembolism prophylaxis only for surgery patients when this survey was conducted, but were nevertheless often used in non-surgery patients. We conducted this "before and after" survey from May 1998 to April 1999 to assess the impact of the recommendations implemented in the beginning of 1999.
  
  
  METHODS
  Data on the use of LMWH were collected on three different days within a three week interval in all non-surgery departments at the Tenon hospital before distribution of expert recommendations early in 1999. Published in La Presse Médicale in January 2000, these recommendations issued from an external panel of 43 experts who were contacted to establish a consensus opinion using the Delphi method. Data were again collected on three different days after implementation of the recommendations. Implementation was based on a patient-specific prescription order form requested by the hospital pharmacy for delivery to the department.
  
  
  RESULTS
  Data were collected for 121 prescriptions prior to the recommendations and for 158 after. Sex-ratio, mean age and percentage of LMWH prescriptions did not differ significantly between the two periods. There was a lower number of non-appropriate prescriptions after implementation of the recommendations from 54.5% to 35.4% (p = 0.01) with better conformity for recommendation A (high-risk patients) (36% versus 43%, NS) and for recommendation B (= 2 risk situations or = 1 risk situation and = 2 aggravating factors) (10% versus 22%, p = 0.01). Better conformity of LMWH prescriptions in oncology and radiotherapy departments partially explained this general improvement, but the difference remained significant when excluding these two departments (p = 0.04).
  
  
  CONCLUSIONS
  This study shows that physician compliance with recognized expert recommendations can improve their implementation. This procedure is now in general use in the Tenon hospital.
authors.affiliation: Hôpital Tenon, 4, rue de la Chine, F 75970 Paris.
authors.forename: J P
authors.initials: JP
authors.lastname: Fagot
authors.forename: A
authors.initials: A
authors.lastname: Flahault
authors.forename: M
authors.initials: M
authors.lastname: Fodil
authors.forename: A
authors.initials: A
authors.lastname: Kanfer
authors.forename: S
authors.initials: S
authors.lastname: Alamowitch
authors.forename: J P
authors.initials: JP
authors.lastname: Haymann
authors.forename: I
authors.initials: I
authors.lastname: Lecomte
authors.forename: H
authors.initials: H
authors.lastname: Lioté
authors.forename: A
authors.initials: A
authors.lastname: Parrot
authors.forename: J
authors.initials: J
authors.lastname: Rossert
authors.forename: E
authors.initials: E
authors.lastname: Verdy
authors.forename: A
authors.initials: A
authors.lastname: Becker
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D005260:Female; D019983:Guideline Adherence; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight